Bronx, New York 10468


Purpose:

Pressure ulcers (PU) are skin breakdowns that often form after blood flow in the skin is reduced from prolonged and repeated exposure to externally applied forces. As many as 85% of individuals with a spinal cord injury (SCI) report the occurrence of at least 1 PU since being injured. Despite the increasing attention and emphasis on prevention, PUs still represent a major health risk for persons with SCI. PUs and other skin breakdowns are at risk for becoming infected; it is not uncommon for many different types of "bugs" to be found in the wound. It has been assumed that the presence of these organisms did not impede wound healing or skin graft survival. The current proposal will use a new type of procedure that involves the direct injection of an antibiotic (in saline) into the skin beneath the wound; it is then distributed throughout the wound using a second device that uses sound waves. The study will determine if the antibiotic treatment and the standard of care improves the rate wound closure compared to the standard of care alone in persons with SCI and a chronic pelvic-region PU.


Criteria:

Inclusion Criteria: 1. Male or female, age 18 to 79; 2. Chronic (e.g., duration of injury at least 6 months), stable SCI (regardless of level of neurological lesion); 3. American Spinal Injury Association Impairment Scale (AIS) designation of A or B with no sensation in the pelvic region; 4. At least one Stage III or IV PU in the pelvic region (e.g., ischial or trochanteric regions) that has not shown signs of healing for a period of at least 1 month; and, 5. Hemoglobin A1C ≤7.0%. Exclusion Criteria: 1. Persons who are candidates for or elect to have reconstructive flap surgery of the PU; 2. Unresolved osteomyelitis diagnosed by clinical impression and supported by one or more of the following: 1) history and examination of the pressure ulcer (i.e., visible bone), 2) bone contact on sterile probe, 3) bone that has lost its normal consistency, 4) magnetic resonance imaging, or 5) open bone biopsy; 3. Hemoglobin A1C >7.0%; 4. Psychopathology (documentation in the medical record or history of self-abusive behavior specific to PU healing which may or may not include major or minor psychiatric illness (that may conflict with the study objectives; 5. Acute illness or systemic infection; 6. Allergy to cefazolin; 7. Allergy to penicillin; 8. History of clinically significant or uncontrolled cardiac disease, including congestive heart failure, angina, myocardial infarction, arrhythmia, including New York Heart Association functional classification of 3; 9. Previously diagnosed active malignant disease; 10. Suspicion of skin cancer at the PU site (i.e., clinical evaluation is currently on-going); 11. Life expectancy less than 12 months; 12. Nephrosis, hemodialysis or chronic ambulatory peritoneal dialysis therapy; 13. Moderate to high dose glucocorticoid administrations (i.e., ≥ 40 mg prednisone or equivalent steroid dose) within the past 3 months; 14. Diminished mental capacity; 15. Inability or unwillingness of subject to provide informed consent; or, 16. Pregnancy or women who may become pregnant during the course of the study, or those who are nursing.


NCT ID:

NCT02584426


Primary Contact:

William A Bauman, MD
Phone: (718) 584-9000 ext. 5428
Email: william.bauman@va.gov


Backup Contact:

Email: joshua.hobson@va.gov
Joshua C Hobson, MS
Phone: (718) 584-9000 ext. 3129


Location Contact:

Bronx, New York 10468
United States

Joshua C Hobson, M.S.
Phone: 718-584-9000
Email: joshua.hobson@va.gov

Site Status: Recruiting


Data Source: ClinicalTrials.gov

Date Processed: January 21, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.